Asian Journal Of Social Pharmacy

Abstract: Objective To study the content of China’s guiding principles on multiplicity issues in clinical trials, and to provide reference for the revision of China’s relevant guiding principles. Methods Based on ICH E9, the similarities and differences of the guiding principles of US Food and Drug Administration (FDA), European Medicines Agency (EMA), and National Medical Products Administration (NMPA) on the multiplicity issues in clinical trials were compared one by one. Results and Conclusion In general, NMPA guidelines are based on ICH E9, but in detail, the guidelines of FDA and EMA focus differently on the multiplicity issues. Therefore, NMPA guidelines need to be detailed and comprehensive. NMPA guidelines can be refined by referring to foreign guidelines to improve the practical guiding significance for clinical research and promote the level of domestic clinical trials in line with international standards.

Key words: clinical trial, multiplicity issue, solution strategy